GAIN THERAPEUTICS, INC Proceeds from Sale and Maturity of Marketable Securities
GAIN THERAPEUTICS, INC (GANX) reported Proceeds from Sale and Maturity of Marketable Securities of $5.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-03-26
- GAIN THERAPEUTICS, INC proceeds from sale and maturity of marketable securities for the quarter ending 2024-12-31 was -$42.50K.
- GAIN THERAPEUTICS, INC proceeds from sale and maturity of marketable securities for the quarter ending 2024-09-30 was $0.00.
- GAIN THERAPEUTICS, INC proceeds from sale and maturity of marketable securities for the quarter ending 2024-06-30 was $2.02M.
- GAIN THERAPEUTICS, INC proceeds from sale and maturity of marketable securities for the quarter ending 2024-03-31 was $3.02M.
- GAIN THERAPEUTICS, INC proceeds from sale and maturity of marketable securities for fiscal 2024 was $5.00M, a 59.00% decline from fiscal 2023.
- GAIN THERAPEUTICS, INC proceeds from sale and maturity of marketable securities for fiscal 2023 was $12.19M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$42.50K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$42.50K derived: sum of 2 quarters · filed 2026-03-26 | $1.98M derived: sum of 3 quarters · filed 2026-03-26 | $5.00M 10-K · filed 2026-03-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.02M derived: sum of 2 quarters · filed 2025-11-12 | $5.04M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $5.04M 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $3.02M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $12.19M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |